FDA Inspection 1238621 — Zhejiang Hisun Pharmaceutical Co., Ltd.
The FDA completed an inspection of Zhejiang Hisun Pharmaceutical Co., Ltd. on Jun 21, 2024 in Taizhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jun 21, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Taizhou (China)